Search

Your search keyword '"Le, Xiuning"' showing total 571 results

Search Constraints

Start Over You searched for: Author "Le, Xiuning" Remove constraint Author: "Le, Xiuning"
571 results on '"Le, Xiuning"'

Search Results

1. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

4. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

5. Analysis of germline-driven ancestry-associated gene expression in cancers

9. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

13. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer

14. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

15. Analytical protocol to identify local ancestry-associated molecular features in cancer

17. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

18. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

19. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

22. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

24. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer

26. Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.

27. FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).

29. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

33. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes

34. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

35. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

36. Structure-based classification predicts drug response in EGFR-mutant NSCLC

38. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival

40. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

41. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype

42. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFRGermline Mutations

43. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

45. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

46. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

47. Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers.

49. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Catalog

Books, media, physical & digital resources